Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Company events

Thumbnail
April 07, 2021

Second-quarter catalysts for the smaller players

Key catalysts approach for Orphazyme, Gemini and Immutep.

Thumbnail
March 30, 2021

Go or no go? The FDA plays hardball

April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.

Article image
Vantage logo
March 25, 2021

Biotech’s important clinical data readouts

The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.

Article image
Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

As Biogen heads towards important depression data, Sanofi looks to oncology for growth.

Article image
Vantage logo
March 19, 2021

Wave gets another shot at Huntington’s

The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.

Article image
Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.

Article image
Vantage logo
March 01, 2021

Go or no go? A delayed decision on Evrenzo

March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.

Article image
Vantage logo
February 22, 2021

Biocryst looks to raise the profile of its factor D inhibitor

The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.

Article image
Vantage logo
February 12, 2021

Novartis’s canakinumab cancer test approaches

Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?

Article image
Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.

Article image
Vantage logo
January 25, 2021

The year immuno-oncology could break into perioperative settings

Keytruda could soon be approved in periadjuvant breast cancer, but adjuvant lung cancer, a bigger setting, is 2021’s big showdown.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.